Financial results - NEOPHARM SRL

Financial Summary - Neopharm Srl
Unique identification code: 6363226
Registration number: J1994000712513
Nace: 4773
Sales - Ron
4.098.445
Net Profit - Ron
-49.807
Employees
31
Open Account
Company Neopharm Srl with Fiscal Code 6363226 recorded a turnover of 2024 of 4.098.445, with a net profit of -49.807 and having an average number of employees of 31. The company operates in the field of Comerţ cu amănuntul al produselor farmaceutice having the NACE code 4773.
Sales - Ron

Sales, Profit, Employees, Total Income, Financial Results - Neopharm Srl

2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Sales - EUR 1.485.961 1.568.263 1.728.924 1.729.786 2.395.580 2.560.539 2.553.024 2.945.067 3.472.671 4.098.445
Total Income - EUR 1.487.828 1.577.143 1.742.940 1.730.999 2.432.037 2.575.751 2.566.100 2.966.016 3.568.696 4.119.857
Total Expenses - EUR 1.459.989 1.552.634 1.703.490 1.705.082 2.333.886 2.441.807 2.468.188 2.886.720 3.490.405 4.169.663
Gross Profit/Loss - EUR 27.839 24.509 39.450 25.917 98.151 133.943 97.912 79.296 78.292 -49.807
Net Profit/Loss - EUR 23.385 18.947 23.140 17.886 81.715 109.808 81.080 62.911 60.956 -49.807
Employees 13 14 15 15 28 28 31 31 31 31
The table presents the most important indicators of the company from the Profit and Loss Account for the last 10 years of activity as found at the Ministry of Finance. The data provides the evolution of the company during this period regarding the increases and possibly decreases recorded. In the last year of activity, the sales increased by 18.7%, from 3.472.671 euro in the year 2023, to 4.098.445 euro in 2024. The Net Profit decreased by -60.615 euro, from 60.956 euro in 2023, to 0 in the last year.
Sales - Ron
Net Profit - Ron
Employees

Check the financial reports for the company - Neopharm Srl

Rating financiar

Financial Rating -
NEOPHARM SRL

See the company's note based on the submitted financial data, relative to the industry of which it is a part.

Financial Rating
Limite de plata

Payment Limits -
Neopharm Srl

See the company's payment capacity for situations in which you conclude contracts with payment terms.

Check Payment Limits
Probabilitate de insolventa

Prob. of insolvency -
Neopharm Srl

It determines the risk of insolvency based on the submitted accounting balance.

Insolvency Probability
Rapoarte financiare

Financial Reports -
Neopharm Srl

Check all the financial reports of the company and know the risks in collaboration with it.

Check Financial Reports
Financial Analysis Reports provide a clear and comprehensive view of a company's financial activity. In addition to presenting financial data, the reports analyze this data so that any user can understand whether the results are positive or less favorable. The Financial Rating provides an analysis based on the most important financial ratios, including liquidity, solvency, and profitability. Payment Limits represent the maximum amounts for which a company can offer goods or services on credit to its clients. The Probability of Insolvency presents the theoretical probability that a company may not be able to meet its financial obligations towards its creditors, i.e., suppliers and financial institutions.

Debts, Equity, Inventories, Receivables, Accounts, Assets - Neopharm Srl - CUI 6363226

2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Fixed Assets 131.670 111.525 108.838 103.553 153.385 139.947 209.683 213.211 214.798 232.786
Current Assets 690.351 617.361 811.298 799.192 894.209 1.025.581 899.648 1.048.885 1.180.413 1.332.336
Inventories 401.530 378.568 427.868 337.179 585.925 665.803 580.049 665.859 740.490 929.207
Receivables 206.483 142.286 301.310 427.813 264.628 319.136 270.542 351.838 410.696 375.558
Cash 27.376 96.506 82.120 34.200 43.656 40.642 49.058 31.188 29.228 27.572
Shareholders Funds 397.968 390.589 340.442 338.840 411.889 455.096 488.838 508.121 556.801 445.804
Social Capital 89.989 89.071 87.564 85.957 107.051 105.022 102.693 103.011 102.699 102.125
Debts 424.053 338.297 579.694 563.904 626.697 703.455 615.489 750.780 837.046 1.117.961
Income in Advance 0 0 0 0 9.009 6.977 5.003 3.194 1.365 1.357
Exchange rate - RON 4.9743 4.9465 4.9315 4.9468 4.8371 4.7454 4.6535 4.5681 4.4908 4.445
Main CAEN "4773 - 4773"
CAEN Financial Year 4773
The table presents the company's Balance Sheet structure for the last 10 years. Current Assets recorded a value of 1.332.336 euro in 2024 which includes Inventories of 929.207 euro, Receivables of 375.558 euro and cash availability of 27.572 euro.
The company's Equity was valued at 445.804 euro, while total Liabilities amounted to 1.117.961 euro. Equity decreased by -107.885 euro, from 556.801 euro in 2023, to 445.804 in 2024. The Debt Ratio was 71.4% in the year 2024.

Risk Reports Prices

Reviews - Neopharm Srl

Comments - Neopharm Srl

Similar services useful for checking companies and business development.

SellNet

Get the contact details for any company and get in touch with it.

Sectoral Studies

Knows the market and develops its own development strategies according to sectorial data.

Databases

Export in excel files the data of the companies selected according to the desired criteria.

Import - Export

Find importers and exporters according to the type of activity and the countries in which they carry it out.

Similar services represent services associated with companies that allow for a better analysis of clients and suppliers. Company Contacts help you get in touch with the desired companies. Sector Studies provide an overview of an industry, the most important competitors, and the geographical distribution of companies. Company Lists allow you to attract new clients, while Import-Export services give you access to companies engaged in such activities.